• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Half of Consumers Will Abandon Health Products Lacking Clear Scientific Evidence, Survey Reveals

by Jasmine Pennic 09/16/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Half of Consumers Will Abandon Health Products Lacking Clear Scientific Evidence, Survey Reveals

What You Should Know: 

A new survey by Lindus Health, a clinical trial company, has reveals that transparency about side effects and long-term safety are the top factors Americans consider when buying health products. 

– The survey, which asked 175 participants about their health-based purchasing behaviors, revealed a significant gap between what consumers want and the information provided by physicians and manufacturers.

– The findings show that less than 14% of respondents follow their physician’s recommendations on health products. In open-ended responses, more than half of the participants said they wished that information on side effects, product usage, and product safety were easier to find. This highlights a pressing unmet need for transparency in consumer health.


The Critical Role of Clinical Evidence

When asked what clinical evidence would most influence their purchase, 29% of respondents cited long-term safety data, 22% wanted before/after clinical data like lab results, and 20% valued self-reported symptom improvement. The research also found that around 46% of respondents have decided against a purchase or stopped using a product due to a lack of clear information or evidence.


Addressing The Trust Gap and the Future of Digital Health

The same concerns about transparency and evidence may be impacting consumer skepticism toward new digital health tools. Only 29% of respondents reported using digital health technologies. The majority continue to rely on traditional options like vitamins and supplements (84%) and OTC medications (59%), which have years of research data and widespread confidence behind them.

Lindus Health aims to address this “trust gap” by delivering high-quality clinical trials, real-world evidence (RWE) studies, and health claims research for consumer health products. The company is focused on generating the robust data needed for consumers to make more informed purchasing decisions.

“The best way to bridge this divide is through high-quality evidence generation—and that’s where Lindus comes in,” said Meri Beckwith, Co-CEO of Lindus Health. “By executing research with consumers’ needs top-of-mind, we’re capturing the data we need so consumers can trust the health products they regularly buy are both safe and effective without sacrificing affordability.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

CB Insights Q2 2026 State of Digital Health Report: Fewest Deals in Over a Decade as Median Sizes Rise

CB Insights Q2 2026 State of Digital Health Report: Fewest Deals in Over a Decade as Median Sizes Rise

mount-sinai-launches-epic-chart-with-art-nursing-ambient-ai

Mount Sinai Medical Center Extends Epic’s Ambient AI to Inpatient Nursing

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

Why Brain Health Is Entering Its Infrastructure Era

Brain Health’s Infrastructure Era: Proving Clinical Outcomes with Integrated Neuromotor Tracking

Why Catholic Health Inked a $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

Catholic Health Inks $500M Care Alliance with GE HealthCare to Automate Outpatient Triage

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

KLAS Global HIT Trends 2026 Report: Artificial Intelligence Becomes the Top Investment Priority

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Optum Partners with Anthropic to Deploy Claude Across Healthcare Claims and Revenue Workflows

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

Rock Health H1 2026 Digital Health Funding Recap: Startups Hit $7.4B in Venture Rebound

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

M&A: ResMed to Sell MatrixCare Business to Frazier Healthcare Partners for $450M

The Real Risk in Healthcare AI Isn’t the Model. It’s the Data. 

Clinical Data Fidelity: The Real Blindspot in Healthcare AI Strategy

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |